Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They presently have a $925.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 3.45% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Truist Financial reiterated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Finally, Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $970.57.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $894.14 on Monday. The stock has a market capitalization of $98.14 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 2.64 and a beta of 0.11. The business has a 50-day moving average of $955.94 and a 200-day moving average of $890.45. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the company posted $10.96 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 38.18 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock valued at $13,124,641 in the last three months. Company insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. West Paces Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Sunbelt Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. O Dell Group LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $27,000. Finally, Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.